< %=imgalt%>
Home / Technology News / 2008 / April 2008 / April 29, 2008
Human immune cell protein opens new front in fighting AIDS virus

Technology News

Hourglass figures not always healthy for women
Having an imperfect body may not be all that bad, says a new article, which claims that imperfections come with substantial benefits for some women. ANI

Sleep terrors may run in the family
A Canadian study of twins suggests that night terrors, which send children into sudden inconsolable screaming, may run in the family. ANI

Swedish scientists make body-swapping a virtual reality
Cognitive neuroscientists at the Swedish medical university Karolinska Institutet (KI) have successfully created the illusion of body swapping by making subjects perceive the bodies of mannequins and other people as their own. ANI

Human immune cell protein opens new front in fighting AIDS virus

A research group supported by the US National Institutes of Health (NIH) has blocked HIV infection in the test tube by inactivating a human protein expressed in key immune cells - a process that may offer a way to circumvent problems with drug resistance.

Washington, Apr 29 : A research group supported by the US' National Institutes of Health (NIH) has blocked HIV infection in the test tube by inactivating a human protein expressed in key immune cells - a process that may offer a way to circumvent problems with drug resistance.

In the new study, Pamela Schwartzberg, M.D., Ph.D., a senior investigator at the National Human Genome Research Institute (NHGRI), part of NIH; Andrew J. Henderson, Ph.D., of Boston University; and their colleagues used a chemical inhibitor and a type of genetic inhibitor, called RNA interference, to inactivate a human protein called interleukin-2-inducible T cell kinase (ITK) in key human immune cells called T cells.

ITK is a signaling protein that activates T cells as part of the body's healthy immune response.

Then, the T cells were exposed to HIV, and the researchers studied the effects of ITK inactivation upon various stages of HIV's infection and replication cycle.

Suppression of ITK reduced HIV's ability to enter T cells and have its genetic material transcribed into new virus particles.

However, ITK suppression did not interfere significantly with T cells' normal ability to survive, and mice deficient in ITK were able to ward off other types of viral infection, although antiviral responses were delayed.

Dr. Schwartzberg said: "Suppression of the ITK protein caused many of the pathways that HIV uses to be less active, thereby inhibiting or slowing HIV replication."

Current drugs used to fight HIV target the virus's own proteins. However, because HIV has a high rate of genetic mutation, those viral targets change quickly and lead to the emergence of drug-resistant viral strains.

"Finding a cellular target that can be inhibited so as to block HIV validates a novel concept and is an exciting model for deriving potential new HIV therapies," said NHGRI Scientific Director Eric D. Green, M.D., Ph.D..

In findings are published in the online edition of the Proceedings of the National Academy of Sciences.

ANI

December 3, 2008

December 2, 2008

December 1, 2008

November 30, 2008

November 29, 2008

November 28, 2008